Literature DB >> 11115240

Chronic inflammatory demyelinating polyradiculoneuropathy: a study of proposed electrodiagnostic and histologic criteria.

R U Haq1, T J Fries, W W Pendlebury, M J Kenny, G J Badger, R Tandan.   

Abstract

OBJECTIVE: To examine the sensitivity of the 3 proposed electrodiagnostic (EDX) criteria for demyelination, the sensitivity and specificity of the proposed Ad Hoc Subcommittee of the American Academy of Neurology AIDS [Acquired Immunodeficiency Syndrome] Task Force histologic criteria (AAN criteria), the degree of agreement among these criteria, and the diagnostic value of sural nerve histologic criteria in patients with idiopathic chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). DESIGN AND METHODS: A retrospective analysis of 24 patients with idiopathic CIDP and 12 patients with diabetic polyneuropathy (DP) who underwent comparable testing of clinical, histologic, and EDX features.
RESULTS: We found 42%, 50%, and 79% sensitivity of the proposed EDX, AAN teased fiber, and AAN electron microscopic (EM) criteria, respectively, for demyelination in CIDP. The specificity of the proposed AAN teased fiber and EM criteria for demyelination was greater than 80% when tested against patients with DP. There was lack of agreement between the EDX and histologic criteria. Almost two thirds of patients with CIDP who met the EM criteria but none of the EDX criteria for demyelination showed a favorable response to immunomodulatory therapy.
CONCLUSIONS: Sural nerve histologic criteria offer unique sensitivity and acceptable specificity toward the diagnosis of CIDP. Sural nerve biopsy should be considered when a clinical suspicion of CIDP remains in patients who do not meet the proposed EDX criteria for demyelination.

Entities:  

Mesh:

Year:  2000        PMID: 11115240     DOI: 10.1001/archneur.57.12.1745

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

Review 1.  How to get the most out of nerve conduction studies and electromyography.

Authors:  G Fuller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

2.  Incidence and prevalence of CIDP and the association of diabetes mellitus.

Authors:  R S Laughlin; P J Dyck; L J Melton; C Leibson; J Ransom; P J B Dyck
Journal:  Neurology       Date:  2009-07-07       Impact factor: 9.910

Review 3.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 4.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

5.  Diagnosing chronic inflammatory demyelinating polyradiculoneuropathy with triple stimulation technique.

Authors:  Du Cao; Xiuming Guo; Ting Yuan; Jie Hao
Journal:  J Neurol       Date:  2018-06-20       Impact factor: 4.849

6.  Further insight on A-wave in acute and chronic demyelinating neuropathies.

Authors:  Ferdinando Sartucci; Tommaso Bocci; Davide Borghetti; Giovanni Orlandi; Francesco Manfredonia; Luigi Murri; Fabio Giannini; Alessandro Rossi
Journal:  Neurol Sci       Date:  2010-06-18       Impact factor: 3.307

Review 7.  Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside.

Authors:  Amanda C Peltier; Peter D Donofrio
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

Review 8.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

Review 9.  Relevance of Nerve Biopsy in the Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy-A Systematic Review.

Authors:  Elena-Sonia Moise; Razvan Matei Bratu; Andreea Hanganu; Maria Sajin
Journal:  Diagnostics (Basel)       Date:  2022-07-11

10.  Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): An Uncommon Manifestation of Systemic Lupus Erythematosus (SLE).

Authors:  Hrudya Abraham; Jose Kuzhively; Syed W Rizvi
Journal:  Am J Case Rep       Date:  2017-09-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.